Abstract:Diabetes is a chronic disease, and needs lifelong treatment. The traditional antidiabetic drugs have their limitations. Sulfonylureas and insulin can increase body weight and induces hypoglycemia. Metformin and a-glycosidase inhibitors result in gastrointestinal reactions. Thiazolidinediones cause edema and weight gain, and increase the risk of heart failure and fractures. Thus, diabetes needs new antidiabetie drugs. After consulting literature, we summarized the drugs for new targets that have been put into market and during ongoing clinical re-search. These drugs include glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 antagonist, sodium glucose co-transporter 2 antagonist, and glucokinase activators. The article introduced their mechanisms, clinical efficacy and safety.

Advance in Clinical Studies of New Antidiabetic Drugs